RYE, NY, December 17, 2014 – Curemark, a leading drug research and development company focused on the treatment of autism and other neurological diseases, announced that Dr. Joan Fallon, CEO and founder, delivered a keynote speech at the Disease Therapeutics Symposia, held at the Courtyard Marriott in Cambridge, MA, December 3-4. Her speech, The Role of Endogenous and Exogenous Amino Acids in the Epigenetics of Neurodegenerative Diseases, took place on Wednesday, December 3.
“We were thrilled to have Dr. Fallon as part of our roster of speakers this year,” said Krishnarao Appasani, Ph.D., MBA, CEO and founder of GeneExpression Systems. “Dr. Fallon joins a group of accomplished academicians and scientists who remain focused on driving forward opportunities for biomedical research in global industry. In particular, her early findings on certain pancreatic enzyme deficiencies and the critical role they may play in the diagnosis and treatment of autism has the potential to deliver first-in-class therapies to many young patients on the spectrum who currently have no available treatment options for their core symptoms.”
Other keynotes were given by:
George Weinstock, PhD., Professor & Associate Director for Microbial Genomics
The Jackson Laboratory for Genomic Medicine, University of Connecticut Health Center
Title: Studies of the medical microbiome
Georg K. Gerber, MD, PhD, MPH, Instructor & Associate Pathologist, Co-Director, Center for Clinical & Translational Metagenomics
Brigham and Women’s Hospital, Harvard Medical School
Title: The dynamic microbiome
Kwanghun Chung, Ph.D., Helmholtz Career Development Assistant Professor
Picower Institute for Learning and Memory, Massachusetts Institute of Technology
Title: CLARITY and beyond: tools for integrated brain mapping
This year’s Symposia consisted of two distinct meetings, co-located under one banner: the fourth annual International Neuron to Synapse & Optogenetics Meeting (entitled Neuronal Function to Mapping & Disease Therapeutics), and the inaugural Microbiome Meeting, (named Gut Biology to Infection, Immune Tolerance & Disease Therapeutics).
GeneExpression Systems is a meeting organization institution on the cutting edge Life Science, Physical Science and Biomedical Science industries that hosts international conferences. The company is situated in the Greater Boston area biotech and hitech hub. Our core competency is to educate the research community by bringing together the authorities from academia (including Nobel laureates, members of the US national academy of sciences and Fellows of the UK Royal Society), biotech, large pharmaceutical and semi-conductor sectors to maintain the motto of “Bridging Academia and Industry.”
GeneExpression Systems Partners with Appasani Research Conferences & Educational Institute (ARCEI.org), US-based nonprofit organization whose mission is to promote global science education. GeneExpression Systems has been incorporated in the Commonwealth of Massachusetts in the year of 1999 by Harvard and MIT trained scientists.
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com